• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Korea·Healthcare·004310.KS
Share

Hyundai Pharmaceutical Co., Ltd. Stocks

₩ 6090Last Updated 07.08.2026

Issuer Rating

3/7
Performance

Favourable

Risk

High

Recommendation

Sell

Market Cap

₩ 86.72M

₩ 6090
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Decent dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Headquartered in Seoul, South Korea, Hyundai Pharmaceutical Co., Ltd. is an international manufacturer and distributor of a diverse portfolio that includes pharmaceutical products, health food beverages, and medical equipment. The company's extensive offerings comprise both prescription (ETC) and over-the-counter (OTC) remedies, addressing a broad spectrum of therapeutic areas. These encompass conditions related to cardiovascular health, infectious diseases, the central nervous system, pain management, respiratory ailments, dermatological issues, digestive and endocrine system disorders, gynecological health, and ophthalmic care. Additionally, their range extends to nutritional supplements, diagnostic reagents, wound healing solutions, and treatments for allergies, arthritis, and anemia, among many others. The company was founded in 1965.

Company Valuation

Fairly valued
4/7

Based on key historical and expected multiples, the stock is fairly valued relative to its peers. Specifically, the stock is 'expensive' on P/E, neutral on EV/EBITD.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

08.08.2026 19:49

Berkshire Hathaway has reduced its "cash cushion" for the first time in four years

08.08.2026 16:01

Small-Cap Highlights: SolarEdge Forecast, Bitdeer's $4.7 Billion Deal, Replimune's Success

08.08.2026 13:01

A Hot Topic from SpaceX, Burry’s Bleak Outlook, and a Touching “Startup” Born Out of Necessity

08.08.2026 12:15

Ukraine has promised the U.S. not to attack the CPC infrastructure in the Black Sea — Bloomberg

08.08.2026 03:20

Billionaire Ekman Identified the Main Risk for Investors in the Anthropic and OpenAI IPOs

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026